[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Date H, Kiura K, Ueoka H, Tabata M, Aoe M, Andou A, Shibayama T, Shimizu N: Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N(2) non-small cell lung cancer. Br J Cancer; 2002 Feb 12;86(4):530-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N(2) non-small cell lung cancer.
  • We conducted a phase I/II study to investigate whether the surgical resection after induction chemotherapy with cisplatin and irinotecan was feasible and could improve the treatment outcome for patients with pathological N(2) non-small cell lung cancer.
  • Fifteen patients with stage IIIA non-small cell lung cancer having mediastinal lymph node metastases proved by mediastinoscopy were eligible.
  • Patients received two cycles of chemotherapy after 3-4 weeks interval.
  • Patients who had documented tumour regression after preoperative chemotherapy received two additional cycles of chemotherapy and other patients received radiotherapy postoperatively.
  • After the induction chemotherapy, the objective response rate was 73%.
  • The median time from entry to final analysis was 46.5 months, ranging from 22 to 68 months.
  • We conclude that the surgical resection after induction chemotherapy with cisplatin and irinotecan is feasible, and associated with low morbidity and high respectability.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Radiotherapy. Remission Induction. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Cancer Res. 1988 Apr 1;48(7):1722-6 [2832051.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Jan;105(1):97-104; discussion 104-6 [8380477.001]
  • [Cites] Ann Thorac Surg. 1993 Apr;55(4):986-9 [8385447.001]
  • [Cites] J Thorac Cardiovasc Surg. 1995 Mar;109(3):473-83; discussion 483-5 [7877308.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1880-92 [7636530.001]
  • [Cites] J Thorac Cardiovasc Surg. 1982 Jan;83(1):1-11 [7054602.001]
  • [Cites] Br J Cancer. 1998 Jul;78(2):257-62 [9683303.001]
  • [Cites] Lung Cancer. 1998 Jul;21(1):1-6 [9792048.001]
  • [Cites] Ann Thorac Surg. 1998 Dec;66(6):1909-14 [9930467.001]
  • [Cites] Br J Cancer. 1999 Feb;79(5-6):984-90 [10070901.001]
  • [Cites] Lung Cancer. 1999 Oct;26(1):7-14 [10574676.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Jan;111(1):123-31; discussion 131-3 [8551756.001]
  • (PMID = 11870532.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2375275
  •  go-up   go-down


2. Arnau Obrer A, Martín Díaz E, Pérez Alonso D, Regueiro Mira F, Cervera Juan A, Granell Gil M, Roch Pendería S, Cantó Armengod A: [Surgical treatment of non-small cell lung cancer with mediastinal node invasion. A retrospective study]. Arch Bronconeumol; 2001 Mar;37(3):121-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of non-small cell lung cancer with mediastinal node invasion. A retrospective study].
  • [Transliterated title] Resultados del tratamiento quirúrgico y terapia neoadyuvante en el cáncer de pulmón no microcítico con invasión ganglionar mediastínica. Estudio retrospectivo.
  • OBJECTIVE: To analyze the survival of patients classified as N2M0 (N2 by cytohistology) with non-small cell lung cancer treated by surgical resection of the primary tumor and lymphadenectomy.
  • PATIENTS AND METHODS: Among 1043 consecutive patients with lung cancer who were considered for surgery between 1990 and 2000, 155 were classified N2M0 by histology.
  • Surgical exeresis of the primarily pulmonary tumor and lymphadenectomy were performed in 116 patients of the 130 patients who underwent thoracotomy.
  • Among the 116 N2M0 patients undergoing surgical resection, 23 were diagnosed N2c(C3) by mediastinoscopy and/or mediastinotomy and were given induction chemotherapy (ChT) (mitomycin/ifosfami-de/cisplatin, 3 cycles) and 93 were diagnosed N2pM0 based on samples obtained from mediastinal lymph tissue during thoracotomy.
  • N2p patients who received induction therapy were given radiotherapy.
  • Those found negative after lymphadenectomy and patients with severe disease were given no adjuvant treatment.
  • Nine patients showed no residual mediastinal node disease after lymphadenectomy.
  • Nine patients developed a bronchopleural fistula.
  • Standard, complete surgery plus induction therapy in screened patients improved survival for those diagnosed N2 by thoracotomy, with no statistically significant differences.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / surgery. Chemotherapy, Adjuvant. Lung Neoplasms / surgery. Lymph Node Excision. Pneumonectomy. Radiotherapy, Adjuvant
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Ifosfamide / administration & dosage. Lymphatic Metastasis. Male. Mediastinoscopy. Mediastinum. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging / methods. Prognosis. Retrospective Studies. Spain / epidemiology. Survival Analysis. Thoracotomy. Treatment Outcome


3. Ma Q, Liu D, Guo Y, Shi B, Song Z, Tian Y: Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2). Zhongguo Fei Ai Za Zhi; 2010 Apr;13(4):342-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2).
  • BACKGROUND AND OBJECTIVE: Approximately 30% of patients who are diagnosed with non-small cell lung cancer (NSCLC) are classified as N2 on the basis of metastasis to the mediastinal lymph nodes.
  • Thus it is necessary to select patients who have a high probability of being be cured through an operation, who are suitable to receive surgery and the best surgical methods so as to figure out the conditions under which surgical treatment can be chosen and the factors that may influence prognosis.
  • The database covers the patients' complete medical history including the information of their age, sex, location and size of tumor, date of operation, surgical methods, histologic diagnosis, clinical stage, post-operative TNM stage, neoadjuvant treatment and chemoradiotherapy.
  • The pathological classification was based on the international standard for lung cancer (UICC 1997).
  • Survival time was analyzed from the operation date to May 2008 with the aid of SPSS (Statistical Package for the Social Sciences) program.
  • RESULTS: The median survival time was 22 months, with 3-year survival rate reaching 28.1% and 5-year survival rate reaching 19.0%.
  • In all N2 subtypes, 5-year survival rate is remarkably higher for unexpected N2 discovered at thoractomy and proven N2 stage before preoperative work-up and receive a mediastinal down-staging after induction therapy (P < 0.01), reaching 30.4% and 27.3% respectively.
  • Induction therapy which downstages proven N2 in 73.3% patients gains them the opportunity of surgery.
  • CONCLUSION: It is suggested that surgery (lobectomy preferentially) is the best solution for T1 and T2 with primary tumor have not invaded pleura or the distance to carina of trachea no less than 2 cm, unexpected N2 discovered at thoractomy when a complete resection can be applied, and proven N2 discovered during preoperative work-up and is down-staged after induction therapy.
  • Surgical treatment is the best option, lobectomy should be prioritized in operational methods since ise rate of complication and morality are lower than that of pneumonectomy.
  • Patients' survival time will not benefit from surgery if they are with lymph nodes metastasis of multiple stations (Bulky N2 included) and T4 which can be partially removed.
  • Neoadjuvant chemotherapy increases long-term survival rate of those with N2 proven prior to surgery.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Lymphatic Metastasis / pathology. Thoracic Surgical Procedures / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677562.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Larsen SS, Krasnik M, Vilmann P, Jacobsen GK, Pedersen JH, Faurschou P, Folke K: Endoscopic ultrasound guided biopsy of mediastinal lesions has a major impact on patient management. Thorax; 2002 Feb;57(2):98-103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound guided biopsy of mediastinal lesions has a major impact on patient management.
  • BACKGROUND: A study was undertaken to evaluate the clinical impact of endoscopic ultrasound guided fine needle aspiration biopsy (EUS-FNA) in patients with mediastinal masses suspected of malignancy.
  • In all patients CT scanning had shown a lesion of the mediastinum suspected of malignancy located adjacent to the oesophagus.
  • RESULTS: For the 79 patients in whom sufficient verification was obtained, EUS-FNA had a sensitivity of 92%, specificity of 100%, PPV of 100%, NPV of 80%, and an accuracy of 94% for cancer of the mediastinum.
  • The direct result of the cytological diagnosis obtained by EUS-FNA was that a final diagnosis of small cell lung cancer was made in eight patients resulting in referral for chemotherapy, and in another three patients with benign disease specific treatment could be initiated (sarcoidosis, mediastinal abscess, and leiomyoma of the oesophagus).
  • CONCLUSIONS: EUS-FNA is a safe and sensitive minimally invasive method for evaluating patients with a solid lesion of the mediastinum suspected by CT scanning.
  • EUS-FNA has a significant impact on patient management and should be considered for diagnosing the spread of cancer to the mediastinum in patients with lung cancer considered for surgery, as well as for the primary diagnosis of solid lesions located in the mediastinum adjacent to the oesophagus.
  • [MeSH-major] Biopsy, Needle / methods. Endosonography / methods. Mediastinal Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Sensitivity and Specificity. Tomography, X-Ray Computed / methods. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cardiovasc Surg (Torino). 2001 Feb;42(1):119-24 [11292919.001]
  • [Cites] Radiology. 2001 Apr;219(1):252-7 [11274566.001]
  • [Cites] J Thorac Cardiovasc Surg. 1986 Jan;91(1):53-6 [3941559.001]
  • [Cites] Chest. 1990 Sep;98(3):586-93 [2203614.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):172-3 [1568614.001]
  • [Cites] Acta Radiol. 1995 May;36(3):326-8 [7742132.001]
  • [Cites] Ann Thorac Surg. 1996 May;61(5):1441-5; discussion 1445-6 [8633956.001]
  • [Cites] Chest. 1996 Aug;110(2):539-44 [8697861.001]
  • [Cites] Eur Radiol. 1996;6(1):19-24 [8797945.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1087-95 [9097990.001]
  • [Cites] Ann Intern Med. 1997 Oct 15;127(8 Pt 1):604-12 [9341058.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Oct;116(4):554-9 [9766582.001]
  • [Cites] Respiration. 1999;66(2):150-5 [10202319.001]
  • [Cites] Ann Thorac Surg. 1985 Dec;40(6):556-60 [4074003.001]
  • [Cites] Endoscopy. 1999 Nov;31(9):707-11 [10604611.001]
  • [Cites] Chest. 2000 Feb;117(2):339-45 [10669672.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2278-84 [11007229.001]
  • [CommentIn] Thorax. 2002 Feb;57(2):95-6 [11828034.001]
  • (PMID = 11828036.001).
  • [ISSN] 0040-6376
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1746251
  •  go-up   go-down


5. Higaki N, Soma I, Hayashi N, Nakano K, Murakami M, Hayashida H, Kan K, Ichihara T, Aizawa N, Saito N, Niju T, Ikeda T, Sakon M: [Advanced lung cancer with mediastinal lymph node metastasis and recurrence of brain metastasis completely responsive to combination chemotherapy and gamma knife radiosurgery--a case report]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2111-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced lung cancer with mediastinal lymph node metastasis and recurrence of brain metastasis completely responsive to combination chemotherapy and gamma knife radiosurgery--a case report].
  • We report a case in which advanced lung cancer with mediastinal lymph node metastasis and recurrence of brain metastasis was completely responsive to combination chemotherapy and gamma knife radiosurgery.
  • The patient was a 61-year-old woman, who suffered from advanced lung cancer (SCC) with bilateral mediastinal lymph node metastasis and contralateral lung nodule.
  • Histological efficacy of both primary lung tumor (SCC) and metastatic brain tumor was evaluated as Ef 3 (pCR).
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Lymphatic Metastasis / pathology. Radiosurgery
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Mediastinum. Middle Aged. Neoplasm Recurrence, Local. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037340.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Hillerdal G, Elmberger G: Malignant mediastinal tumor with bone formation--mesothelioma or sarcoma? J Thorac Oncol; 2007 Oct;2(10):983-4
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mediastinal tumor with bone formation--mesothelioma or sarcoma?
  • Here, we report a 57-year old man who presented with a mediastinal tumor containing scattered irregular calcifications with some scattered pleural thickening of the right pleura.
  • Since the tumor was pressing against the large vessels and heart, a debulking was performed, followed by Pemetrexed and Carboplatin treatment.
  • However, the tumor grew rapidly and spread to the pleura, involved the heart, and the patient succumbed.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Mesothelioma / pathology. Osteogenesis. Sarcoma / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Calcification, Physiologic. Carboplatin / administration & dosage. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Male. Middle Aged. Pemetrexed. Pleural Effusion, Malignant / drug therapy. Pleural Effusion, Malignant / etiology. Pleural Neoplasms / drug therapy. Pleural Neoplasms / pathology. Thoracoscopy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909365.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


7. Phernambucq EC, Biesma B, Smit EF, Paul MA, vd Tol A, Schramel FM, Bolhuis RJ, Postmus PE: Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease). Br J Cancer; 2006 Aug 21;95(4):470-4
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease).
  • To assess the therapeutic activity of accelerated cisplatin and high-dose epirubicin with erythropoietin and G-CSF support as induction therapy for patients with stage IIIa-N2 non-small-cell lung cancer (NSCLC).
  • Depending on results of clinical response to induction therapy and restaging, patients were treated with surgery or radiotherapy.
  • During 169 courses of induction chemotherapy, National Cancer Institute of Canada (NCI-C) grade III/IV leucocytopenia was reported in 35 courses (20.7%), NCI-C grade III/IV thrombocytopenia in 26 courses (15.4%) and NCI-C grade III/IV anaemia in six courses (3.6%).
  • There were no chemotherapy-related deaths.
  • After induction therapy, 30 patients underwent surgery; complete resection was achieved in 19 procedures (31.1%).
  • Six patients were considered unfit for further treatment.
  • Response rate of accelerated cisplatin and high-dose epirubicin as induction chemotherapy for stage IIIa-N2 NSCLC patients is not different from more commonly used cisplatin-based regimen.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Epirubicin / administration & dosage. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Erythropoietin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Lymphatic Metastasis. Male. Mediastinum. Middle Aged. Pneumonectomy. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 1999 Oct;26(1):7-14 [10574676.001]
  • [Cites] JAMA. 2005 Aug 24;294(8):931-6 [16118383.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Comput Assist Tomogr. 2000 Jan-Feb;24(1):35-40 [10667655.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2658-64 [10894864.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1826-31 [11156079.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Jun;19(6):894-8 [11404148.001]
  • [Cites] Br J Cancer. 2001 Nov 16;85(10):1456-61 [11720428.001]
  • [Cites] Ann Thorac Surg. 2002 Jan;73(1):259-64; discussion 264-6 [11834020.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1752-9 [12721251.001]
  • [Cites] Lung Cancer. 2003 Oct;42(1):69-77 [14512190.001]
  • [Cites] Lung Cancer. 2003 Dec;42(3):355-61 [14644524.001]
  • [Cites] Ann Thorac Surg. 2004 Jan;77(1):254-9; discussion 259 [14726072.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Eur J Cancer. 1993;29A Suppl 2:S2-8 [8398361.001]
  • [Cites] Oncology. 1995 Sep-Oct;52(5):422-6 [7637961.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1218-34 [9060566.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3412-25 [9779721.001]
  • [Cites] Lung Cancer. 1998 Jul;21(1):1-6 [9792048.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 May;15(5):608-14 [10386405.001]
  • [Cites] Lung Cancer. 2005 Jan;47(1):103-9 [15603860.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(11):1560-9 [15953714.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):516-25 [15965493.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8362-70 [16293866.001]
  • (PMID = 16909132.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 11096-26-7 / Erythropoietin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2360660
  •  go-up   go-down


8. Wang Z, Qi W, Zhu Y, Lin R: [The Clinical Application of Video Mediastinoscopy and CT in the N Staging of Preoperative Lung Cancer.]. Zhongguo Fei Ai Za Zhi; 2009 Oct 20;12(10):1085-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The Clinical Application of Video Mediastinoscopy and CT in the N Staging of Preoperative Lung Cancer.].
  • BACKGROUND: Preoperative lung cancer with mediastinal lymph nodes metastasis can be diagnosed by vedio mediastinoscopy (VM) and CT.
  • This study was to explore the value of VM and CT in the diagnosis of N staging of preoperative lung cancer, and to discuss the difference between the two methods.
  • METHODS: Forty-eight cases diagnosed of lung cancer by CT or PET-CT were examined by VM.
  • The sensitivity, specificity, validity, positive predictive value and negative predictive value of VM and CT were speculated according to the postoperative pathological reports, and the difference between VM and CT in the diagnosis of lung cancer with mediastinal lymph nodes metastasis was discussed.
  • RESULTS: (1)Under the examination of VM, 31 patients with the negative outcome received the direct operation; 14 patients with N2 received 2 courses of neoadjuvant chemotherapy before operation; 3 patients with N3 received chemotherapy and/or radiotherapy. (2)Forty-one cases with final diagnosis of lung cancer were used as samples to speculate the sensitivity, specificity, validity, positive predictive value and negative predictive value of VM.
  • CONCLUSIONS: VM is superior to CT in the diagnosis of N staging of preoperative lung cancer; Due to its safety and effectiveness, VM will be wildly used in the field of thoracic surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723347.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Petrova MV, Korniak AV, Krasnova TE: [Antibiotic prophylaxis of postoperative complications in surgical treatment of pulmonary, tracheal and mediastinal tumors]. Anesteziol Reanimatol; 2001 Sep-Oct;(5):58-60
Hazardous Substances Data Bank. NETILMICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Antibiotic prophylaxis of postoperative complications in surgical treatment of pulmonary, tracheal and mediastinal tumors].
  • A protocol of antibiotic protection, developed and used at Russian Research Center of Roentgenoradiology, is presented.
  • This protocol of perioperative treatment is intended for control of a spectrum of bacterial infections retrospectively detected in patients with lung, tracheal, and mediastinal cancer.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Antibiotic Prophylaxis. Cephalosporins / therapeutic use. Lung Neoplasms / surgery. Mediastinal Neoplasms / surgery. Penicillins / therapeutic use. Postoperative Complications / prevention & control. Tracheal Neoplasms / surgery
  • [MeSH-minor] Amikacin / administration & dosage. Amikacin / therapeutic use. Amoxicillin / administration & dosage. Amoxicillin / therapeutic use. Anti-Infective Agents / administration & dosage. Anti-Infective Agents / therapeutic use. Carbapenems / administration & dosage. Carbapenems / therapeutic use. Cefazolin / administration & dosage. Cefazolin / therapeutic use. Cefuroxime / administration & dosage. Cefuroxime / therapeutic use. Clavulanic Acid / administration & dosage. Clavulanic Acid / therapeutic use. Drug Therapy, Combination. Gentamicins / administration & dosage. Gentamicins / therapeutic use. Humans. Metronidazole / administration & dosage. Metronidazole / therapeutic use. Middle Aged. Netilmicin / administration & dosage. Netilmicin / therapeutic use. Pneumonectomy. Ticarcillin / administration & dosage. Ticarcillin / therapeutic use. Time Factors

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CEFAZOLIN .
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. AMIKACIN .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11757305.001).
  • [ISSN] 0201-7563
  • [Journal-full-title] Anesteziologiia i reanimatologiia
  • [ISO-abbreviation] Anesteziol Reanimatol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Carbapenems; 0 / Cephalosporins; 0 / Gentamicins; 0 / Penicillins; 140QMO216E / Metronidazole; 23521W1S24 / Clavulanic Acid; 4O5J85GJJB / Netilmicin; 804826J2HU / Amoxicillin; 84319SGC3C / Amikacin; F93UJX4SWT / Ticarcillin; IHS69L0Y4T / Cefazolin; O1R9FJ93ED / Cefuroxime
  •  go-up   go-down


10. Beran S: [Superior vena cava syndrome--potential of the intervention therapy]. Cas Lek Cesk; 2006;145(5):349-52
Genetic Alliance. consumer health - Superior vena cava syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Superior vena cava syndrome--potential of the intervention therapy].
  • Superior vena cava syndrome is a relatively frequent complication in patient with lung or mediastinal cancer.
  • Standard treatment is usually based on radiotherapy or chemotherapy.
  • These methods appear to be more effective in the treatment superior vena cava obstruction or stenosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755768.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 31
  •  go-up   go-down


11. Lemarié E: [Clinical types of thoracic cancer. Mediastinal tumours]. Rev Mal Respir; 2006 Nov;23(5 Pt 3):16S170-16S176

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical types of thoracic cancer. Mediastinal tumours].
  • [Transliterated title] Formes cliniques des cancers thoraciques. Tumeurs du médiastin.
  • Mediastinal germ cell tumours (teratomas, seminomas, and non-seminomatous malignant germ cell tumours) are a heterogeneous group of benign and malignant neoplasms.
  • The standard treatment of mediastinal non-seminomatous malignant germ cell tumours is four cycles of chemotherapy followed by surgical resection of the residual mass.
  • Small localized mediastinal seminomas may be treated with primary resection followed by radiotherapy.
  • In patients with locally advanced disease, the preferred treatment is systemic chemotherapy followed by surgical resection of any residual disease.
  • Radiation therapy is usually recommended for invasive or incompletely excised tumours.
  • [MeSH-major] Mediastinal Neoplasms
  • [MeSH-minor] Humans. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / therapy. Thoracic Neoplasms. Thymoma / diagnosis. Thymoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268355.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 25
  •  go-up   go-down


12. Teraishi F, Kagawa S, Uno F, Takeda H, Takigawa N, Fujiwara T, Tanaka N: [Successfully resected stage IIIA non-small cell lung cancer with mediastinal lymphnode metastasis after chemotherapy of cisplatin and docetaxel combined with concurrent radiation]. Gan To Kagaku Ryoho; 2007 Sep;34(9):1493-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successfully resected stage IIIA non-small cell lung cancer with mediastinal lymphnode metastasis after chemotherapy of cisplatin and docetaxel combined with concurrent radiation].
  • A 47-year-old man with no symptoms was admitted to our hospital for the treatment of NSCLC, which was incidentally detected by an X-ray examination at the mass screening.
  • Computed tomography (CT) of the chest and FDG-PET revealed a 3.6 cm tumor in the right upper lobe with multiple lymphadenopathy in the right mediastinum.
  • The patient consented to and received 2 courses of systemic chemotherapy consisting of cisplatin (CDDP 40 mg/m(2); day 1, 8) and docetaxel (DOC 40 mg/m(2); day 1, 8) combined with concurrent radiation (2 Gy/day; total 46 Gy) with no severe adverse events.
  • His tumors responded well to the treatment, and restaging chest CT showed marked regression of mediastinal lymphadenopathy, and partial response to the lung tumor.
  • Our chemotherapy regimen consisting of CDDP and DOC combined with concurrent radiation might be as potent as neo-adjuvant therapy for clinical stage III NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Small Cell / therapy. Combined Modality Therapy. Lung Neoplasms / therapy. Lymphatic Metastasis
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876154.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Tieu BH, Sanborn RE, Thomas CR Jr: Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement. Thorac Surg Clin; 2008 Nov;18(4):403-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
  • The optimal treatment for stage IIIA (N2) NSCLC remains controversial.
  • Numerous studies with induction chemotherapy or chemoradiotherapy show that both approaches in the neoadjuvant setting are feasible.
  • Outcomes following induction therapy have been associated with mediastinal nodal response, with residual mediastinal involvement a negative predictor of survival.
  • Appropriate selection of patients to undergo resection following induction therapy is critical.
  • Lobectomy may be safely performed following induction therapy while pneumonectomy may carry a high and possibly unacceptable rate of perioperative mortality.
  • Combined modality therapy has increased the overall survival of patients with stage III NSCLC.
  • Future trials looking at different induction regimens with or without radiotherapy and with or without surgery may help identify the ideal treatment for this heterogeneous disease stage.
  • The SAKK-16/00 study is an ongoing phase III European trial randomizing patients with stage IIIA NSCLC to receive neoadjuvant chemotherapy with three cycles of docetaxel and cisplatin followed by radiation and then surgical resection, or to chemotherapy with the same regimen followed by surgery alone.
  • The RTOG 0229 phase II study is evaluating neoadjuvant paclitaxel and carboplatin concurrently with radiation therapy, followed by surgery and consolidation chemotherapy with paclitaxel and carboplatin for stage III NSCLC.
  • The combination of neoadjuvant docetaxel, carboplatin, and radiation therapy followed by surgical resection for stage III NSCLC is also currently being investigated in a phase II trial.
  • The future of treatment for stage III NSCLC may lie in the outcome of trials investigating molecularly targeted agents, such as EGFR inhibitors, anti-angiogenic agents, or multitargeted agents.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoadjuvant Therapy / methods. Pneumonectomy / methods
  • [MeSH-minor] Humans. Lymphatic Metastasis. Mediastinum. Neoplasm Staging


14. Sanborn RE, Lally BE: Adjuvant therapy for non-small cell lung cancer with mediastinal nodal involvement. Thorac Surg Clin; 2008 Nov;18(4):423-35
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy for non-small cell lung cancer with mediastinal nodal involvement.
  • Since the publication of the meta-analysis in 1995 indicating a potential survival benefit with adjuvant cisplatin-based chemotherapy for patients with resected NSCLC, the management of patients with resected NSCLC and N2 disease involvement has evolved dramatically.
  • The delivery of systemic therapy in the postoperative setting remains difficult, however, because tolerance for the toxicities of chemotherapy is reduced by recovery from surgery itself.
  • Even with a proven survival benefit with adjuvant chemotherapy, cure is not guaranteed, and most patients die from relapse of their cancer.
  • Optimization of treatment through the administration of neoadjuvant therapy, application of more modern radiotherapy techniques, and combined-modality therapy with chemoradiation or molecularly targeted agents are areas currently under active investigation.
  • Ideally, the improvement of prediction of which patients harbor micrometastatic disease before undergoing surgical resection and the prediction of which patients would benefit from different systemic therapies may help to improve further the chance of cure for NSCLC while at the same time reducing toxicity.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Humans. Lymphatic Metastasis. Mediastinum. Neoplasm Staging. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19086611.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 66
  •  go-up   go-down


15. De Waele M, Hendriks J, Lauwers P, Ortmanns P, Vanroelen W, Morel AM, Germonpré P, Van Schil P: Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy. Eur J Cardiothorac Surg; 2006 Feb;29(2):240-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy.
  • OBJECTIVE: Remediastinoscopy is a valuable tool in restaging non-small cell lung cancer after induction therapy for mediastinal nodal involvement as it provides pathological evidence of response and may select patients for subsequent thoracotomy.
  • METHODS: From November 1994 to April 2003, a remediastinoscopy was performed in 32 patients (29 men, 3 women) after induction therapy for locally advanced non-small cell lung cancer.
  • Neoadjuvant chemotherapy was given in 26 patients and chemoradiotherapy in 6.
  • Median survival time for the whole group was 21 months (95% confidence interval [CI] 9-33).
  • Median survival time in patients with a positive remediastinoscopy was 7 months (95% CI 5-9), with a negative remediastinoscopy 41 months (95% CI 13-69), and with a false-negative remediastinoscopy 24 months (95% CI 5-43).
  • In the combined group of patients with positive and false-negative remediastinoscopies (n=17), median survival time was 8 months (95% CI 3-13).
  • CONCLUSIONS: Remediastinoscopy is a valuable restaging procedure after induction therapy.
  • Prognosis is poor in patients with persisting mediastinal nodal involvement, proven at repeat mediastinoscopy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Mediastinoscopy. Middle Aged. Neoplasm Staging. Postoperative Period. Prognosis. Remission Induction / methods. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16386916.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Miura K, Yoshizawa K, Tamaki M, Okumura K, Furukita Y: [Mediastinal lymph node carcinoma of unknown primary site; report of a case]. Kyobu Geka; 2009 Mar;62(3):255-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mediastinal lymph node carcinoma of unknown primary site; report of a case].
  • A 44-year-old woman was admitted to our hospital because of mediastinal mass.
  • The tumor was resected through right thoracotomy.
  • She was diagonosed as metastatic mediastinal lymph node carcinoma of unknown primary site.
  • She received radiotherapy and chemotherapy and is desease free 29 months after operation.
  • Good results may be obtained by multimodality therapies for cancer in mediastinal lymph node of unknown primary site.
  • [MeSH-major] Adenocarcinoma / secondary. Lymph Nodes / pathology. Mediastinal Neoplasms / secondary. Neoplasms, Unknown Primary
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Combined Modality Therapy. Female. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280962.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


17. Ikeda N, Tsuboi M, Ohira T, Hirano T, Kato H: [Guidelines for the treatment of lung cancer with lymph node involvement]. Nihon Geka Gakkai Zasshi; 2004 Jul;105(7):404-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Guidelines for the treatment of lung cancer with lymph node involvement].
  • Lung cancer with mediastinal lymph node involvement has a poor prognosis, especially when treated with surgery alone.
  • Such cases are considered to be managed best by multimodality treatment.
  • Some randomized trials showed positive results of induction chemotherapy and adjuvant chemotherapy in locally advanced lung cancer, but more evidence is needed to create the standard treatment for stage III lung cancer.
  • A combination of chemotherapy and radiotherapy remain the standard of care for patients with obvious N2 disease, and the role of surgery following induction chemotherapy or chemo-radiotherapy in advanced stage III patients will be evaluated in phase III trials.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Guideline Adherence. Lung Neoplasms / therapy. Lymph Nodes / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Humans. Lymphatic Metastasis. Pneumonectomy

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15303439.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 20
  •  go-up   go-down


18. Friedrich RE: Mental neuropathy (numb chin syndrome) leading to diagnosis of metastatic mediastinal cancer. Anticancer Res; 2010 May;30(5):1819-21
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mental neuropathy (numb chin syndrome) leading to diagnosis of metastatic mediastinal cancer.
  • Neuropathy of the mental nerve is a rare condition that demands accurate differential diagnosis.
  • Plain radiographs and computerised tomography (CT) scans revealed the mental foramen on the top of the toothless mandible and a symmetrically depicted mandibular canal.
  • Surgical exploration demonstrated a tumour inside the mandibular canal, not visible on radiographs.
  • Subsequently performed CT scans revealed an extensive mediastinal tumour with metastasis to multiple lymph nodes and further metastases to the kidney and liver.
  • Diagnosis was small-cell bronchial carcinoma (extensive disease, stage grouping II B, Marburg classification).
  • Palliative chemotherapy was ineffective and the patient died with evidence of tumour progression.
  • The cause of a numb chin needs to be clarified further, and the syndrome should be seriously considered, using thorough diagnosis, including the surgical revision of the affected nerve.
  • [MeSH-major] Chin / innervation. Mediastinal Neoplasms / pathology. Trigeminal Nerve Diseases / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / pharmacology. Carcinoma / diagnosis. Carcinoma / pathology. Disease Progression. Foreign-Body Reaction. Humans. Jaw / pathology. Male. Neoplasm Metastasis. Palliative Care. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592385.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Maisch B, Ristic A, Pankuweit S: Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis; 2010 Sep-Oct;53(2):157-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a considerable number of patients with breast or lung cancer or with mediastinal lymphoma, in addition to direct involvement by the tumor, radiation therapy as well as systemic tumor treatment can also lead to pericardial effusion.
  • In addition, in immunosuppressed tumor patients, pericardial effusion can also arise from viral, bacterial, and autoimmune causes.
  • To distinguish between these 3 different conditions leading to pericardial effusion, the diagnosis should be based on pericardiocentesis followed by fluid analysis for cytology and biomarkers, on epicardial and pericardial biopsy facilitated by flexible pericardioscopy with analysis of specimens by conventional histology and molecular biology techniques for viral and microbial aetiology.
  • We collected prospectively but analyzed retrospectively 357 patients undergoing pericardiocentesis from 1988 to 2008 and identified 68 patients who had cancer-related pericardial effusion.
  • With these methods, 42 patients demonstrated malignant effusion, 15 patients had radiation-induced pericardial, effusion, and in 11 patients without radiation therapy, the effusion could be attributed to either viral infection in 5 cases or to an autoimmune process in the remaining 6 patients.
  • Consequently, intrapericardial treatment could be tailored for each cohort: neoplastic effusion was treated with intrapericardial cisplatin (single instillation of 30 mg/m(2) per 24 hours); in addition to the tumor-specific systemic chemotherapy, intrapericardial triamcinolone acetate (Volon A) was given in a dose of 500 mg/m(2) in the patients with autoimmune and radiation-induced effusion.
  • Saline rinsing and intrapericardial sclerosing treatment were the treatment of choice in viral pericardial effusion.
  • Oral colchicine treatment (2-3 x 0.5 mg) was given in all patients for at least 3 months.
  • This differential diagnostic approach and the results of treatment were compared with published series.
  • [MeSH-major] Neoplasms / therapy. Pericardial Effusion / diagnosis. Pericardial Effusion / therapy. Radiation Injuries / diagnosis. Radiation Injuries / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Bacterial Infections / complications. Biomarkers / analysis. Biopsy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pericardiocentesis. Polymerase Chain Reaction. Predictive Value of Tests. Radiotherapy / adverse effects. Recurrence. Registries. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. Virus Diseases / complications

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20728703.001).
  • [ISSN] 1873-1740
  • [Journal-full-title] Progress in cardiovascular diseases
  • [ISO-abbreviation] Prog Cardiovasc Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers
  •  go-up   go-down


20. Kiyotoki S, Nishikawa J, Tanimoto H, Saito M, Hamabe K, Okamoto T, Noguchi T, Sakaida I: [A case of effective photodynamic therapy for local recurrence after definitive chemoradiotherapy for esophageal cancer]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2055-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of effective photodynamic therapy for local recurrence after definitive chemoradiotherapy for esophageal cancer].
  • We performed a photodynamic therapy for local recurrence after chemoradiotherapy for esophageal cancer.
  • Esophagoscopy, CT and FDG-PET revealed an advanced esophageal cancer with mediastinal lymph node metastasis.
  • He rejected a surgical treatment and underwent chemoradiotherapy, then achieved CR once.
  • Endoscopic biopsy specimen from Lugol's unstained lesion of the esophagus revealed squamous cell carcinoma, and he was diagnosed as a recurrence of the esophageal cancer.
  • He underwent chemotherapy again, but the recurrent lesion enlarged.
  • Because the control of the metastatic lesion was excellent and the recurrent lesion was considered as a superficial cancer, he was performed photodynamic therapy.
  • Two months after photodynamic therapy, the esophagoscopy and FDG-PET showed no findings of the recurrence of the esophageal cancer.
  • It was suggested that photodynamic therapy for local recurrence after definitive chemotherapy for esophageal cancer was effective and relatively safe.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Photochemotherapy
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037321.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Stoelben E, Digel W, Henke M, Passlick B: [Multimodal treatment of non small cell lung cancer]. Zentralbl Chir; 2006 Apr;131(2):110-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multimodal treatment of non small cell lung cancer].
  • [Transliterated title] Multimodale Therapie des nichtkleinzelligen Bronchialkarzinoms.
  • The primary treatment of lung cancer depends on tumor stage.
  • In case of lung cancer without mediastinal lymph node enlargement or direct mediastinal involvement (clinical stage I-IIb + T3N1) surgical treatment is recommended.
  • The use of adjuvant chemotherapy has to be defined, but will be indicated in stage II and IIIa.
  • Expected 5-year survival achieves 40 to 80 % depending on tumor stage.
  • Exceeds the shorter diameter of mediastinal lymph nodes in chest CT scan more than 1 cm (or in case of positive PET scan) mediastinoscopy is indicated.
  • In case of N2-disease and after tumor response to preoperative chemotherapy (about 60 %) secondary resection of the tumor leads to higher 5-year survival rates (20-40 %) compared to patients without induction therapy (5-20 %).
  • In these patients and after unexpected detection of solitary lymph node metastasis by primary resection adjuvant mediastinal radiotherapy should be added.
  • If the tumor has infiltrated the mediastinum or the upper sulcus (T3/4) and/or mediastinal lymph nodes are obviously tumor burden (e. g. > 3 cm, N2 bulky, N3) radical primary resection may not be possible.
  • In these patients combined radio- and chemotherapy induces a high percentage of tumor regression and can be used before secondary resection (5-year survival 5-20 %).
  • Locally advanced tumors infiltrating the main bronchus close to the carina or the carina itself and tumors with metastases in the same lobe, both without mediastinal lymph node metastases (T3/4N0-1), can be resected by sleeve pneumonectomy and lobectomy with satisfactory results respectively.
  • In patients with resectable lung cancer and no clinical sign of tumor disease (f. e. anemia, weight loss, pain) limited staging procedure with chest CT scan including upper abdomen and bronchoscopy is reasonable.
  • We recommend an interdisciplinary approach to patients with lung cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Bronchogenic / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Neoadjuvant Therapy. Pneumonectomy
  • [MeSH-minor] Bronchoscopy. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Lymph Node Excision. Mediastinoscopy. Neoplasm Staging. Palliative Care. Radiotherapy, Adjuvant. Software Design. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612776.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Okubo K, Kobayashi M, Morikawa H, Hayatsu E: Easier node dissection after chemoradiotherapy for lung cancer with collagen insertion at mediastinoscopy. Jpn J Thorac Cardiovasc Surg; 2006 Jul;54(7):268-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Easier node dissection after chemoradiotherapy for lung cancer with collagen insertion at mediastinoscopy.
  • OBJECTIVE: Induction chemoradiotherapy followed by anatomical resection is a current therapeutic strategy for non-small-cell lung cancer with mediastinal node involvement.
  • Dense peritracheal fibrosis and sclerosis after chemoradiotherapy cause difficult mediastinal node dissection.
  • We evaluated a novel technique to make the mediastinal node dissection easier after induction therapy.
  • METHODS: At the end of mediastinoscopic node biopsy for staging of lung cancer, cotton-type collagen was inserted anterior and lateral to the trachea in patients with pathologically confirmed mediastinal node involvement (n=45).
  • The induction therapy consisted of concurrent use of platinum-based chemotherapy and hyperfractionated radiotherapy.
  • After the chemoradiotherapy all patients underwent a pulmonary resection with complete mediastinal node dissection 7-12 weeks after the collagen insertion.
  • Surgical findings of the mediastinum and the time for node dissection were compared with those without collagen insertion at mediastinoscopy after chemoradiotherapy (n=5).
  • RESULTS: All five patients without collagen insertion showed sclerotic and fibrotic change of mediastinal nodes with severe adhesion to the trachea.
  • In 42 of 45 patients with collagen insertion (93.3%) the collagen remained unabsorbed and separated the mediastinal nodes from the trachea.
  • Mediastinal node dissection was easily accomplished by removing mediastinal tissues lateral and anterior to the collagen.
  • The rate of mediastinal node separation was significantly higher with collagen insertion than without (p<0.0001).
  • The times for node dissection in patients with and without collagen insertion showed no significant difference.
  • CONCLUSION: Cotton-type collagen insertion at staging mediastinoscopy for lung cancer separates the mediastinal nodes from the trachea and makes the node dissection easier after induction chemoradiotherapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / therapy. Collagen / therapeutic use. Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Lymph Node Excision. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / surgery. Mediastinoscopy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Japan. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Sentinel Lymph Node Biopsy. Trachea / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16898638.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9007-34-5 / Collagen
  •  go-up   go-down


23. Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H: Induction therapy for non-small cell lung cancer with involved mediastinal nodes in multiple stations. Chest; 2000 Jul;118(1):123-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction therapy for non-small cell lung cancer with involved mediastinal nodes in multiple stations.
  • BACKGROUND: Metastasis to multiple stations of mediastinal nodes is associated with a poor prognosis.
  • OBJECTIVE: : We prospectively examined the efficacy of induction therapy plus surgery in patients with non-small cell lung cancer and metastases at multiple stations of mediastinal (N2) lymph nodes.
  • METHODS: Among the 1,085 patients who underwent surgery for primary non-small cell lung carcinoma from 1985 to 1997, those with clinical N2 disease of involved multiple stations, defined as bulky, mediastinal, lymph node metastases on CT scans, received induction therapy, consisting of cisplatin-based chemotherapy and radiation of 40 Gy.
  • Neither operative mortality nor fatal, treatment-related complications occurred during hospitalization.
  • Among patients with multiple stations of pN2 nodes involved who had undergone complete resection, those who received induction therapy for bulky N2 disease had a significantly better prognosis than did those undergoing surgery alone for nonbulky N2 disease (p = 0.03).
  • CONCLUSIONS: Induction therapy prolonged the survival of patients with non-small cell lung cancer and mediastinal nodes involved at multiple stations.
  • Survival was better when complete resection and downstaging of the disease were achieved after induction therapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis. Male. Mediastinum. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10893369.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


24. Larsen SS, Krasnik M, Vilmann P, Jacobsen GK, Pedersen JJ, Faurschou P, Folke K: [Endoscopic ultrasound-guided biopsy of suspected malignancy in the mediastinum has a major impact on the clinical decision process]. Ugeskr Laeger; 2002 Jun 17;164(25):3341-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic ultrasound-guided biopsy of suspected malignancy in the mediastinum has a major impact on the clinical decision process].
  • [Transliterated title] Endoskopisk UL-vejledt biopsi af malignitetssuspekte processer i mediastinum har stor indflydelse på den kliniske beslutningsproces.
  • INTRODUCTION: A study was undertaken to evaluate the clinical impact of endoscopic ultrasound-guided, fine needle aspiration biopsy (EUS-FNA) in patients with mediastinal masses suspected of malignancy.
  • In all patients computer tomography (CT) had shown a lesion of the mediastinum suspected of malignancy, which was located adjacent to the oesophagus.
  • RESULTS: For the 79 patients, in whom sufficient verification was obtained, EUS-FNA had a sensitivity of 92%, a specificity of 100%, a positive predictive value of 100%, a negative predictive value of 80%, and an accuracy of 94% for cancer in the mediastinum.
  • The direct result of the cytological diagnosis obtained by EUS-FNA was that a final diagnosis of small cell lung cancer was made in eight patients leading to referral for chemotherapy, and specific therapy could be initiated in another three patients with benign disease (sarcoidosis, mediastinal abscess and leiomyoma of the oesophagus).
  • DISCUSSION: EUS-FNA is a safe and sensitive, minimal invasive method in the evaluation of patients with a solid lesion of the mediastinum, suspected by CT.
  • EUS-FNA has a significant impact on patient management; it should be considered for diagnosing the spread of cancer to the mediastinum of patients with lung cancer in whom surgery is contemplated, as well as for the primary diagnosis of solid lesions located in the mediastinum adjacent to the oesophagus.
  • [MeSH-major] Endosonography. Mediastinal Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Biopsy, Needle / methods. Decision Making. Female. Humans. Lung Neoplasms / radiography. Lung Neoplasms / therapy. Lung Neoplasms / ultrasonography. Male. Middle Aged. Predictive Value of Tests. Referral and Consultation. Sensitivity and Specificity. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12107948.001).
  • [ISSN] 0041-5782
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


25. Kesler KA: Surgical techniques for testicular nonseminomatous germ cell tumors metastatic to the mediastinum. Chest Surg Clin N Am; 2002 Nov;12(4):749-68
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical techniques for testicular nonseminomatous germ cell tumors metastatic to the mediastinum.
  • Since 1980, the author and his colleagues have performed over 400 thoracic surgical procedures to remove residual mediastinal disease after cisplatin-based chemotherapy in nearly 300 patients with testicular nonseminomatous germ cell tumors [6].
  • The 10-year survival rate has been 78% from the time of diagnosis with removal of benign residual mediastinal disease pathologically consisting of either necrosis or teratoma.
  • Commonly, multiple surgical procedures are required to remove bilateral or multiple levels of residual mediastinal disease or disease that presents during long-term follow-up.
  • Prolonged survival seems possible following the resection of limited areas of persistent nonseminomatous germ cell tumors or nonseminomatous germ cell tumor degeneration into non-germ cell cancer within the mediastinum.
  • Salvage surgery to remove chemotherapy-refractory mediastinal disease represents a situation in which significantly poorer long-term survival is anticipated; however, an aggressive surgical approach is justified in select patients.
  • [MeSH-major] Germinoma / secondary. Germinoma / surgery. Mediastinal Neoplasms / secondary. Testicular Neoplasms / pathology. Thoracotomy / methods
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Combined Modality Therapy. Dissection / methods. Humans. Male. Neoplasm Metastasis. Neoplasm, Residual. Patient Selection. Prognosis. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12471876.001).
  • [ISSN] 1052-3359
  • [Journal-full-title] Chest surgery clinics of North America
  • [ISO-abbreviation] Chest Surg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 13
  •  go-up   go-down


26. Malani AK, Gupta C, Singh J, Rangineni S: A 63-year-old woman with colon cancer and mediastinal lymphadenopathy. Chest; 2007 Jun;131(6):1970-3
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 63-year-old woman with colon cancer and mediastinal lymphadenopathy.
  • [MeSH-major] Colonic Neoplasms / complications. Lymphatic Diseases / radionuclide imaging. Sarcoidosis / complications
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis / radionuclide imaging. Mediastinal Diseases / etiology. Mediastinal Diseases / radionuclide imaging. Middle Aged. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565032.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement